{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:34Z","timestamp":1789588594863,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000346","name":"Ataxia UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Friedreich\u2019s ataxia (FA) is an inherited progressive neurodegenerative disease for which there is no proven disease-modifying treatment. Here we perform an open\u2010label, pilot study of recombinant human granulocyte-colony stimulating factor (G-CSF) administration in seven people with FA (EudraCT: 2017-003084-34); each participant receiving a single course of G-CSF (Lenograstim; 1.28 million units per kg per day for 5 days). The primary outcome is peripheral blood mononuclear cell frataxin levels over a 19-day period. The secondary outcomes include safety, haematopoietic stem cell (HSC) mobilisation, antioxidant levels and mitochondrial enzyme activity. The trial meets pre-specified endpoints. We show that administration of G-CSF to people with FA is safe. Mobilisation of HSCs in response to G-CSF is comparable to that of healthy individuals. Notably, sustained increases in cellular frataxin concentrations and raised PGC-1\u03b1 and Nrf2 expression are detected. Our findings show potential for G-CSF therapy to have a clinical impact in people with FA.<\/jats:p>","DOI":"10.1038\/s41467-022-31450-w","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:03:15Z","timestamp":1660039395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich\u2019s ataxia"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-1309","authenticated-orcid":false,"given":"Kevin C.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-2174","authenticated-orcid":false,"given":"Anastasia","family":"Georgievskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-584X","authenticated-orcid":false,"given":"Kelly","family":"Hares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-9399","authenticated-orcid":false,"given":"Steven","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-4426","authenticated-orcid":false,"given":"Claire M.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-1043","authenticated-orcid":false,"given":"Neil J.","family":"Scolding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-8907","authenticated-orcid":false,"given":"Chris","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-8078","authenticated-orcid":false,"given":"Alastair","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"31450_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen, A. H. Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303, 1\u201312 (2011).","journal-title":"J. Neurol. Sci."},{"key":"31450_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano, V. et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423\u20131427 (1996).","journal-title":"Science"},{"key":"31450_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jnc.12303","volume":"126","author":"P Gonzalez-Cabo","year":"2013","unstructured":"Gonzalez-Cabo, P. & Palau, F. Mitochondrial pathophysiology in Friedreich\u2019s ataxia. J. Neurochem. 126, 53\u201364 (2013).","journal-title":"J. Neurochem."},{"key":"31450_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch, D. R., Perlman, S. L. & Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch. Neurol. 67, 941\u2013947 (2010).","journal-title":"Arch. Neurol."},{"key":"31450_CR5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","volume":"15","author":"JM Cooper","year":"2008","unstructured":"Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L. & Schapira, A. H. Coenzyme Q10 and vitamin E deficiency in Friedreich\u2019s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15, 1371\u20131379 (2008).","journal-title":"Eur. J. Neurol."},{"key":"31450_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo, M. et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76, 509\u2013521 (2014).","journal-title":"Ann. Neurol."},{"key":"31450_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/mds.24066","volume":"27","author":"C Mariotti","year":"2012","unstructured":"Mariotti, C. et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov. Disord. 27, 446\u2013449 (2012).","journal-title":"Mov. Disord."},{"key":"31450_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ane.12337","volume":"132","author":"L Seyer","year":"2015","unstructured":"Seyer, L. et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol. Scand. 132, 7\u201315 (2015).","journal-title":"Acta Neurol. Scand."},{"key":"31450_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","volume":"384","author":"V Libri","year":"2014","unstructured":"Libri, V. et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich\u2019s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384, 504\u2013513 (2014).","journal-title":"Lancet"},{"key":"31450_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ana.25207","volume":"83","author":"KC Kemp","year":"2018","unstructured":"Kemp, K. C. et al. Bone marrow transplantation stimulates neural repair in Friedreich\u2019s ataxia mice. Ann. Neurol. 83, 779\u2013793 (2018).","journal-title":"Ann. Neurol."},{"key":"31450_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.24846","volume":"81","author":"KC Kemp","year":"2017","unstructured":"Kemp, K. C. et al. Cytokine therapy-mediated neuroprotection in a Friedreich\u2019s ataxia mouse model. Ann. Neurol. 81, 212\u2013226 (2017).","journal-title":"Ann. Neurol."},{"key":"31450_CR12","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00277-017-3060-4","volume":"96","author":"R Farhan","year":"2017","unstructured":"Farhan, R. et al. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Ann. Hematol. 96, 1735\u20131739 (2017).","journal-title":"Ann. Hematol."},{"key":"31450_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jacc.2005.01.067","volume":"46","author":"JM Hill","year":"2005","unstructured":"Hill, J. M. et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 46, 1643\u20131648 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"31450_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1242\/dmm.030502","volume":"10","author":"H Lin","year":"2017","unstructured":"Lin, H. et al. Early cerebellar deficits in mitochondrial biogenesis and respiratory chain complexes in the KIKO mouse model of Friedreich ataxia. Dis. Model Mech. 10, 1343\u20131352 (2017).","journal-title":"Dis. Model Mech."},{"key":"31450_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1089\/ars.2012.4537","volume":"19","author":"Y Shan","year":"2013","unstructured":"Shan, Y. et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model. Antioxid. Redox Signal 19, 1481\u20131493 (2013).","journal-title":"Antioxid. Redox Signal"},{"key":"31450_CR16","doi-asserted-by":"publisher","first-page":"e10025","DOI":"10.1371\/journal.pone.0010025","volume":"5","author":"D Marmolino","year":"2010","unstructured":"Marmolino, D. et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich\u2019s ataxia. PLoS One 5, e10025 (2010).","journal-title":"PLoS One"},{"key":"31450_CR17","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00520-016-3119-0","volume":"24","author":"J Moukharskaya","year":"2016","unstructured":"Moukharskaya, J. et al. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer 24, 3085\u20133093 (2016).","journal-title":"Support Care Cancer"},{"key":"31450_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1503\/cmaj.051322","volume":"174","author":"WC Shyu","year":"2006","unstructured":"Shyu, W. C., Lin, S. Z., Lee, C. C., Liu, D. D. & Li, H. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 174, 927\u2013933 (2006).","journal-title":"CMAJ"},{"key":"31450_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cyto.2014.02.003","volume":"67","author":"J Grassinger","year":"2014","unstructured":"Grassinger, J. et al. Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine 67, 21\u201328 (2014).","journal-title":"Cytokine"},{"key":"31450_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.expneurol.2006.12.001","volume":"204","author":"LR Zhao","year":"2007","unstructured":"Zhao, L. R. et al. Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp. Neurol. 204, 569\u2013573 (2007).","journal-title":"Exp. Neurol."},{"key":"31450_CR21","doi-asserted-by":"publisher","first-page":"11572","DOI":"10.1523\/JNEUROSCI.0453-09.2009","volume":"29","author":"K Diederich","year":"2009","unstructured":"Diederich, K. et al. The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice. J. Neurosci. 29, 11572\u201311581 (2009).","journal-title":"J. Neurosci."},{"key":"31450_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1172\/JCI23559","volume":"115","author":"A Schneider","year":"2005","unstructured":"Schneider, A. et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest. 115, 2083\u20132098 (2005).","journal-title":"J. Clin. Invest."},{"key":"31450_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/vox.12754","volume":"114","author":"D Furst","year":"2019","unstructured":"Furst, D. et al. Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors. Vox Sang. 114, 275\u2013282 (2019).","journal-title":"Vox Sang."},{"key":"31450_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2337\/db13-0894","volume":"63","author":"M Albiero","year":"2014","unstructured":"Albiero, M. et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 63, 1353\u20131365 (2014).","journal-title":"Diabetes"},{"key":"31450_CR25","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00415-018-8946-0","volume":"265","author":"E Indelicato","year":"2018","unstructured":"Indelicato, E. et al. Autonomic function testing in Friedreich\u2019s ataxia. J. Neurol. 265, 2015\u20132022 (2018).","journal-title":"J. Neurol."},{"key":"31450_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1634\/stemcells.22-5-704","volume":"22","author":"YJ Summers","year":"2004","unstructured":"Summers, Y. J. et al. AC133+ G0 cells from cord blood show a high incidence of long-term culture-initiating cells and a capacity for more than 100 million-fold amplification of colony-forming cells in vitro. Stem Cells 22, 704\u2013715 (2004).","journal-title":"Stem Cells"},{"key":"31450_CR27","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1021\/acs.analchem.7b04590","volume":"90","author":"L Guo","year":"2018","unstructured":"Guo, L. et al. Liquid chromatography-high resolution mass spectrometry analysis of platelet Frataxin as a protein biomarker for the rare disease Friedreich\u2019s ataxia. Anal. Chem. 90, 2216\u20132223 (2018).","journal-title":"Anal. Chem."},{"key":"31450_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/jnnp.2003.028605","volume":"75","author":"L Pianese","year":"2004","unstructured":"Pianese, L. et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J. Neurol. Neurosurg. Psychiatry 75, 1061\u20131063 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"31450_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","volume":"10","author":"W Nachbauer","year":"2011","unstructured":"Nachbauer, W. et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia\u2013a dose-response trial. Cerebellum 10, 763\u2013769 (2011).","journal-title":"Cerebellum"},{"key":"31450_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.aca.2009.11.036","volume":"659","author":"H Steinkellner","year":"2010","unstructured":"Steinkellner, H., Scheiber-Mojdehkar, B., Goldenberg, H. & Sturm, B. A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Anal. Chim. Acta 659, 129\u2013132 (2010).","journal-title":"Anal. Chim. Acta"},{"key":"31450_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04593-w","volume":"7","author":"HI Choi","year":"2017","unstructured":"Choi, H. I. et al. PGC-1alpha attenuates hydrogen peroxide-induced apoptotic cell death by upregulating Nrf-2 via GSK3beta inactivation mediated by activated p38 in HK-2 Cells. Sci. Rep. 7, 4319 (2017).","journal-title":"Sci. Rep."},{"key":"31450_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F","volume":"34","author":"M Keeney","year":"1998","unstructured":"Keeney, M. et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 34, 61\u201370 (1998).","journal-title":"Cytometry"},{"key":"31450_CR33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony, S. H. et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261\u20131262 (2005).","journal-title":"Neurology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31450-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:31:03Z","timestamp":1669314663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31450-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31450"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31450-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4655"}}